Join
Live feed
·
PRReleasevia Quantisnow
Synlogic Inc. logo

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

ByQuantisnow·Wall Street's wire, on your screen.
SYBX· Synlogic Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SYBX (Synlogic Inc.) and more on Quantisnow.